Assessing Financial Difficulty in Patients With Blood Cancers Save

Date Added
April 16th, 2020
PRO Number
Pro00089787
Researcher
Irl Greenwell

List of Studies

Silhouette
Keywords
Cancer, Cancer/Leukemia, Cancer/Myeloma
Summary

This study is for patients that have been diagnosed with either chronic lymphocytic leukemia, multiple myeloma or both. The purpose of this study is to estimate the proportion of patients with MM and/or CLL who report experiencing financial difficulty in the past 12 months. Participants will complete a telephone survey within 8 weeks after joining the study.

Institution
MUSC
Recruitment Contact
Barbara Roe
843-652-1607
broe@tidelandshealth.org

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lonalidomide as Post-Autologous STem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration Save

Date Added
November 6th, 2019
PRO Number
Pro00094224
Researcher
Amarendra Neppalli

List of Studies

Silhouette
Keywords
Cancer, Cancer/Myeloma
Summary

This study is for patients that have been diagnosed with multiple myeloma. The investigational drugs in this study are lenalidomide and daratumumab. The purpose of this study is to compare overall survival between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma patients. Participants can expect to be on this study for up to 7 years. After 7 years, participants may be followed by telephone for up to 15 years from the time they started study treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Save

Date Added
July 29th, 2019
PRO Number
Pro00090904
Researcher
Amarendra Neppalli

List of Studies

Silhouette
Keywords
Cancer, Cancer/Myeloma
Summary

This study is for patients that have been diagnosed with smoldering multiple myeloma (SMM). The drugs used in this study are daratumumab, lenalidomide and dexamethasone which are all commercially used drugs. The purpose of this study is to compare overall survival in patients with high-risk smoldering multiple myeloma randomized to daratumumab revlimid-dexamethasone or revlimid-dexamethasone. Participants can expect to be on this study for up to two years and followed by your doctor for up to 15 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Reduced Pressure Reaming versus Standard Reaming for the Treatment of Impending Pathologic Femur Fractures Save

Date Added
January 16th, 2018
PRO Number
Pro00063851
Researcher
Lee Leddy

List of Studies


Profiles_link
Keywords
Bone, Cancer, Cancer/Lymphoma, Cancer/Myeloma, Cancer/Other, Cancer/Sarcoma, Surgery
Summary

This study is for patients that have suffered a femur fracture due to metastatic cancer. The standard of care for this type of fracture is to stabilize the bone with an intramedullary nail. When preparing the femur for the nail, pressure can cause fat to enter the bloodstream and travel to the heart, causing heart and lung complications. The procedure being investigated in this study is called reduced pressure reaming. In this procedure the surgeon will use a device with suction when preparing the bone for the nail in order to decrease pressure and decrease the amount of fat that enters the bloodstream. Patients will be randomly assigned to either the standard preparation (standard reaming), or the reduced pressure preparation (reduced pressure reaming). After surgery, both treatment groups will followed according to standard practices at 2 weeks, 6 weeks, 3 months, and 6 months.

Institution
MUSC
Recruitment Contact
Robert McClam
843-792-7238
mcclamr@musc.edu

Change_preferences

-- OR --

Create_login